ARJUNA Therapeutics announces the appointment of Dr Robert Barnes to the Board of Directors
Dr Barnes is Group Head of Securities Trading at London Stock Exchange Group (LSEG) and CEO of Turquoise, the European share trading platform majority owned by LSEG. Prior to joining LSEG in 2013, Dr Barnes worked at UBS in various roles, including as a Managing Director, Equities, and founding CEO of UBS MTF. With more than 27 years of Capital Markets experience, he is an industry expert on market structures and has held a wide range of key advisory and policy roles in the financial services sector. Robert is a Chartered Fellow of the Chartered Institute for Securities & Investment and holds a PhD in Biotechnology from Cambridge University and a BA in Biochemical Sciences from Harvard.
Ross Breckenridge FRCP, PhD, CEO and Chairman of ARJUNA Therapeutics said: "I'm delighted that Robert has joined our Board. His broad and deep understanding of financial markets and the business world will be of great value to the company as we move into the clinic and beyond".
Dr Barnes said: "I am honoured to join the ARJUNA team and look forward to helping the company in its goal of changing the way cancer is treated."
ARJUNA Therapeutics is developing a novel small molecule platform, Therapeutic Molecular Clusters (TMCs), to address the largest unmet clinical needs in oncology.
Dr Robert Barnes – Biography
2013 – present London Stock Exchange Group (LSEG)
2013 Anopolis Limited – Founder & Managing Director
1994 – 2013 UBS – Managing Director since 2005
Education & professional qualifications
2010 Chartered Fellow of the Chartered Institute for Securities & Investment (CISI)
1994 Cambridge PhD, Biotechnology
1989 Harvard BA, Biochemical Sciences
For more information about Arjuna Therapeutics, visit our website: